Pharma Mar, S.A.
PHMMFOTCHealthcare● Active
$106.48
+$0.00(+0.00%)
Market Cap$1.8B
P/E Ratio—
52W High$110.4
52W Low$80.91
Pharma Mar, S.A. (PHMMF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PHMMF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.22B | $0.17B | $0.16B | $0.20B | $0.23B |
| Cost of Revenue | $0.01B | $0.01B | $0.01B | $0.01B | $0.02B |
| Gross Profit | $0.21B | $0.17B | $0.15B | $0.18B | $0.21B |
| Gross Margin %(computed) | 94.46% | 95.32% | 93.92% | 93.05% | 92.85% |
| Operating Expenses | |||||
| R&D Expenses | $0.10B | $0.10B | $0.10B | $0.08B | $0.07B |
| G&A Expenses | $0.00B | ($0.00B) | $0.02B | $0.02B | $0.02B |
| Total Operating Expenses | $0.17B | $0.16B | $0.15B | $0.14B | $0.12B |
| Operating Income | $0.04B | $0.01B | ($0.00B) | $0.04B | $0.09B |
| Operating Margin %(computed) | 18.19% | 3.70% | -2.42% | 22.45% | 40.22% |
| Interest Income | $0.00B | $0.01B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | $0.06B | $0.01B | ($0.00B) | $0.04B | $0.10B |
| Income Tax Expense | ($0.02B) | ($0.01B) | ($0.00B) | ($0.01B) | $0.00B |
| Net Income | $0.07B | $0.03B | $0.00B | $0.05B | $0.09B |
| Net Margin %(computed) | 33.87% | 14.94% | 0.72% | 25.14% | 40.40% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $4.36 | $1.49 | $0.06 | $2.73 | $5.14 |
| Wtd Avg Shares | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B |
| EBITDA | $0.05B | $0.02B | $0.00B | $0.05B | $0.10B |
| EBITDA Margin %(computed) | 21.81% | 12.14% | 2.88% | 26.52% | 45.29% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · EUR · B
Explore more Pharma Mar, S.A. data
About Pharma Mar, S.A. (PHMMF) Income Statement
Pharma Mar, S.A. (PHMMF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, PHMMF reported revenue of $0.22B, gross profit of $0.21B (gross margin 94.46%), and net income of $0.07B — a net profit margin of 33.87%.
Frequently asked questions
PHMMF · 4 questionsPharma Mar, S.A. (PHMMF) reported revenue of $0.22B for 2025, up 26.6% year-over-year.
PHMMF revenuePHMMF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09